Following a collaboration that started in 2021, Ardena is proud to see Kupando reach a key milestone with the first patient dosed in the Phase 1 clinical study of KUP101, its lead candidate for the treatment of advanced solid tumors.
Kupando has announced the successful dosing of the first patient in the Phase 1 clinical study of KUP101, a differentiated dual Toll-Like Receptor (TLR) 4/7 agonist being evaluated in patients with advanced solid tumors.
This achievement marks an important step in the development of KUP101 and reflects Kupando’s evolution into a clinical-stage biopharmaceutical company. It also represents several years of pharmaceutical development, manufacturing and cross-functional collaboration focused on bringing the program into clinical evaluation.
A partnership built over several years
Kupando and Ardena have worked together on the development of KUP101 since 2021. Throughout this period, teams at Ardena’s sites in Oss and Ghent provided integrated pharmaceutical development and manufacturing support to help advance the program toward first-in-human clinical evaluation.
The collaboration combined expertise across process development, analytical sciences, manufacturing, fill & finish activities and clinical supply preparation, creating a coordinated pathway from development through clinical trial readiness.
Reflecting on the milestone, Ardena’s Nanomedicines team in Oss and the Drug Product and CMC Regulatory teams in Ghent emphasize the strength of the long-standing partnership behind the program:
“Advancing an innovative development program into clinical evaluation takes close collaboration, scientific problem-solving and dedication across multiple disciplines. Reaching the first patient dosed milestone for KUP101 is a significant achievement for Kupando, and the Ardena teams are proud to have supported the program.”
Reaching an important milestone
The first patient dosed milestone follows the release of the first GMP clinical batch earlier in 2026 and represents the successful transition of KUP101 from pharmaceutical development into clinical evaluation.
For all organizations involved, the achievement reflects strong scientific, technical and operational collaboration focused on ensuring that clinical trial material was developed, manufactured and supplied to the standards required for human studies.
As KUP101 now enters clinical evaluation, the program will generate the data needed to assess safety and guide future development decisions.
Looking ahead
While clinical development remains at an early stage, the first patient dosed milestone is a significant moment for the KUP101 program and for everyone who has contributed to its development journey.
Ardena congratulates the entire Kupando team on this achievement and looks forward to supporting the next phases of the program.
